alexa Determination of Rocuronium in Human Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry and its Pharmacokinetics in Patients | Open Access Journals
ISSN: 0975-0851
Journal of Bioequivalence & Bioavailability
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Determination of Rocuronium in Human Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry and its Pharmacokinetics in Patients

Yuan Guiyan, Zhang Rui, Wang Benjie, Wei Chunmin, Liu Xiaoyan, Zhao Wenjing and Guo Ruichen*

Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan Shandong, China

*Corresponding Author:
Guo Ruichen
Institute of Clinical Pharmacology
Qilu Hospital of Shandong University
Jinan Shandong, China
Tel: (0351)82169636
Fax: (0531)86109975
E-mail: [email protected]

Received Date: October 23, 2012; Accepted Date: October 27, 2012; Published Date: October 31, 2012

Citation: Guiyan Y, Rui Z, Benjie W, Chunmin W, Xiaoyan L, et al. (2012) Determination of Rocuronium in Human Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry and its Pharmacokinetics in Patients. J Bioequiv Availab 4: xxix-xxx. doi: 10.4172/jbb.10000e23

Copyright: © 2012 Guiyan Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Bioequivalence & Bioavailability

Keywords

Rocuronium; High performance liquid chromatographytandem mass spectrometry; Pharmacokinetics

Introduction

Rocuronium, a new type of muscle relaxant with the features of single quaternary ammonium steroids, medium aging and non depolarizing, was used for anesthesia and surgery of endotracheal intubation of muscle relaxation, which has quick effect, short duration and no cumulative effect, and do not produce tachycardia and blood pressure change, no histamine release, and other features. It is one of the most widely used muscle relaxants at present [1,2].

Less studies were reported on the determination of rocuronium. Yu et al. [3] reported a gas chromatography mass spectrometric (GCMS) method for determination rocuronium in human plasma, which has higher limit of quantitation and longer time for sample analysis. Shi et al. [4] developed a high performance liquid chromatography with fluorescence detection (HPLC-FD) method to determine the concentration of rocuronium in patient’s plasma, which sample treatment was time-consuming because of rocuronium derivatization. Farenc et al. [5] established a high performance liquid chromatographymass spectrometric (LC-MS) method to determine the concentration of rocuronium in human plasma. In this method, the limit of quantitation is higher (25 ng-mL-1), and trifluoroacetic acid was added to the mobile phase which can damage the ion source because it is less volatile. The aims of this paper were to establish a LC-MS/MS method to determine rocuronium in human plasma and to study the pharmacokinetics of rocuronium in patients used the established method.

Experimental

Chemical, regents and instruments

Rocuronium standard (purity>99%, Batch number 63254132) was provided by Organon Pharmaceutical Co Ltd (Oss, Netherlands). Lorazepam standard (Batch number 171253-200401) was provided by national institutes for food and control. HPLC grade methanol and acetonitrile (Batch number LOTG06E10 and LOTE30818) were purchased from J.T. Baker Company (USA). Analytical pure ammonium acetate (Batch number 060223) was provided by Chemical Industry Institute of Shandong Province (Jinan, China).

The HPLC components consisted of an Agilent 1200 liquid chromatography system with a G1312B binary pump, G1379B degasser, G1316B thermostated column compartment and G1367C auto-sampler (Agilent Technologies, USA). An Agilent 6410 triple quadrupole mass spectrometer equipped with a Turbo Ion Spray (ESI) source was used for mass analysis and detection (Agilent Technologies, USA).

Chromatographic conditions

Chromatographic separation was performed using a Agilent SB C18 column (3.5 μm particle size, 150×2.1 mm internal diameter; Agilent Technologies). The isocratic mobile phase consisted of methanol/ acetonitrile/20 mM ammonium acetate buffer solution (20/40/40, v/v/v). The flow rate of the mobile phase and the column oven temperature were set at 0.7 mL/min and 20°C, respectively.

Mass spectrometric conditions

The ESI source was set to positive ion mode and multiple reaction monitoring (MRM) mode was used to detect rocuronium and lorazepam (internal standard, IS) at the transition of 529.3→487.3 and 321.0→275.0, with spray gas pressure of 40 psi, protective air of nitrogen gas at a flow rate of 9 L/min, capillary voltage of 4000 V, fragment electric voltage of 100 V, and collision energy of 45 eV for rocuroniumand 20 eV for I.S.

Sample preparation

A 25 μL aliquot of the I.S. solution (10 μg/mL) and 300 μL mixture of methanol/acetonitrile (1/1, v/v) were added to 200 μL of plasma samples, mixed on a Multi-Tube Vortexer VX-02 (TARGIN TECH CO., Ltd) for 1 minute, followed by 5 minutes centrifugation at 11132x g. A 5 μL of upper organic layer was injected for HPLC/MS/MS analysis.

Pharmacokinetic study design

Seven patients, who will undergo a surgery using rocuronium as anesthetic, signed the informed consent form after understanding the content, rights, obligations and risks. 4 mL blood samples were collected in heparinized tubes before (0) and 2, 4, 9, 15, 25, 40, 60, 90, 120, 180, 240, and 360 min after hocused. Blood samples were centrifuged at 1752x g for 10 minutes and plasma was subsequently quoted and stored at –20°C until analyzed. Drug and Statistic (DAS, version 2.0, by Chen et al. [6], China) was used to calculate the main pharmacokinetic parameters as half life (t1/2) and area under the plasma concentration versus time curve (AUC0-24 and AUC0-&infin ;). The peak plasma concentration (Cmax) and its corresponding time (Tmax) were observed values.

Results

Method validation

Specificity was assessed by analyzing six different human blank plasma samples.

Typical chromatograms are shown in Figure 1. Matrix effects were evaluated by signal response comparison of six extracted blank plasma samples with those of six analytical standards (at three concentration levels of QCs). No matrix effects were detected in the study.

bioequivalence-bioavailability-chromatograms-blank

Figure 1: a) Chromatograms of blank plasma. B) Plasma spiked with r��������ocuronium
and IS standard, c) Extracted plasma sample from a patient spiked with IS
(a-rocuronium, a-IS).

The calibration curves were constructed by analyzing five independent standard plasma samples. The peak area ratios of rocuronium and IS were measured and plotted against the concentrations of rocuronium spiked with blank plasma, and the least square method with 1/x2 weighting factor was used. The weighted regression equation was y=12.2106x+0.0354 with a correlation coefficient r2 of 0.9976. It was found to be linear over the range of 5-3000 μg/mL.

The extraction recoveries of rocuronium were determined by comparing the mean peak areas of the extracted QC samples at 3 concentrations of 10, 100, 2000 μg/mL with mean peak areas of appropriate concentrations of standard solutions. The results were found to be 92.0, 92.9 and 92.6% with a precision (RSD) of 1.68, 0.71 and 1.22%, respectively.

Precision and accuracy were assessed investigating. QC samples on three different validation days. The intra-day precision (RSD) ranged between 1.10 and 1.95%, while the inter-day precision (RSD) ranged between 3.97 and 8.05%.

The freeze-thaw and freeze stabilities of rocuronium were evaluated by analyzing QC samples undergoing two freeze-thaw cycles (–20°C to room temperature) and placing QC samples at –20°C for 24 h and 7 days. The stability results suggested that rocuronium was stable under these storage and processing conditions.

Pharmacokinetic study

The concentration of rocuronium in patient’s plasma was determined using the established LC-MS/MS method. The main pharmacokinetic parameters of rocuronium were as follows: t1/2=78.18 ± 26.88 min, Tmax=2.29 ± 0.76 min, Cmax=27.99 ± 48.93 μg/ mL, AUC0-360=276.93 ± 220.56 μg/mL·h, AUC0-&infin ;=279.67 ± 220.29 μg/mL.h.

Conclusion

A sensitive and selective LC-MS method was developed and validated for the determination of rocuronium in human plasma. This has been successfully applied to pharmacokinetic studies in patients who were hocused using rocuronium.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11645
  • [From(publication date):
    November-2012 - Aug 18, 2017]
  • Breakdown by view type
  • HTML page views : 7863
  • PDF downloads :3782
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords